Nomination Committee

Clarification to the PR Regarding Proposal for Change in the Board of Directors for Nanologica AB (publ)

2 September, 2024

The clarification is that it is the nomination committee of Nanologica AB that has presented the proposal to elect Alexandra Blomberg Montgomery to the board of directors of Nanologica AB. The nomination committee, consisting of Carl-Johan Spak (Flerie Invest AB), Lennart Francke (Swedbank Robur funds), and Kalle Olby (Vega Bianca AB), has in connection with Nanologica AB preparing an Extraordinary General Meeting to be held on 23 September 2024, resolved to propose that the board

Förtydligande till PM gällande förslag till förändring av styrelsen för Nanologica AB (publ)

2 September, 2024

Förtydligandet gäller att det är valberedningen för Nanologica AB som framlagt förslaget om att välja in Alexandra Blomberg Montgomery till styrelsen för Nanologica AB. Valberedningen, bestående av Carl-Johan Spak (Flerie Invest AB), Lennart Francke (Swedbank Robur fonder), samt Kalle Olby (Vega Bianca AB), har i samband med att Nanologica AB förbereder en extrastämma att hållas den 23 september 2024, beslutat föreslå att styrelsen utökas med en ledamot, nämligen Alexandra Blomberg Montgomery. Valberedningen har intervjuat Alexandra Blomberg

Förslag till förändring av styrelsen för Nanologica AB (publ)

2 September, 2024

Alexandra Blomberg Montgomery föreslås att vid den extra bolagsstämman 23 september 2024 väljas in som ny styrelseledamot i Nanologicas styrelse. Alexandra Blomberg Montgomery har lång erfarenhet av rådgivning till bolag verksamma inom många sektorer genom sina år som partner på KREAB där hon även innehaft flera ledande befattningar bl a inom internationell affärsutveckling. Vidare har Alexandra erfarenhet av medicinsk forskning utifrån ett styrelseperspektiv, exempelvis som styrelseledamot i Ragnar Söderbergs Stiftelse. Alexandra arbetar främst med investeringar i

Proposal for Change in the Board of Directors of Nanologica AB (publ)

2 September, 2024

Alexandra Blomberg Montgomery is proposed to be elected as a new member of the board of directors of Nanologica at the Extraordinary General Meeting on September 23, 2024. Alexandra Blomberg Montgomery has extensive experience in advising companies operating in several sectors through her years as a partner at KREAB, where she has also held several senior positions, including in international business development. Furthermore, Alexandra has experience of medical research from a board perspective, for example

Nanologica Announces Nomination Committee for the Annual General Meeting 2024

26 October, 2023

In accordance with the resolution at the Annual General Meeting (“AGM”) on May 4, 2023, the chairman of the board has contacted Nanologica’s three largest owners or ownership groups in terms of votes as of September 30, 2023, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2024 AGM. The nomination committee for Nanologica AB's 2024 AGM thus consists of the following three members: Carl-Johan Spak (Flerie

Nanologicas valberedning utsedd inför årsstämman 2024

26 October, 2023

I enlighet med beslut på årsstämman den 4 maj 2023 har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2023, som var och en har utsett en representant att utgöra valberedning i Nanologica AB inför årsstämman 2024. Valberedningen inför Nanologica AB:s årsstämma 2024 utgörs därmed av följande tre ledamöter: Carl-Johan Spak (Flerie Invest AB) Lennart Francke (Swedbank Robur Microcap) Kalle Olby (Vega Bianca AB) Valberedningen representerar tillsammans 53,3 procent

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.